
CyberLogic, Inc. is a company specializing in research and development in biomedical and electrical engineering, with a strong focus on ultrasonic technologies. We have developed and obtained FDA approval for a novel bone sonometer, the UltraScan™ 650, that is the only ultrasound medical device that accurately and reproducibly measures bone mineral density (BMD), without the ionizing radiation of DXA. CyberLogic has also developed and markets ultrasound simulation software (Wave2000, Wave25000, and Wave3000) that is used worldwide in non-destructive testing, imaging, and transducer design, among other applications.
CyberLogic is presently engaged in further development of ultrasonic bone assessment technology. We provide research and development in the fields of biomedical and electrical engineering, including the fields of ultrasonics, biomechanics, orthopedics, electromagnetics, system identification, signal processing, stochastic systems and computational methods. The backgrounds of the people associated with CyberLogic are primarily in electrical engineering but there are strong ties to both biomedical and mechanical engineering as well.
Previous work concerned the investigation of biophysical stimulation of biological systems, including both electromagnetic and ultrasonic stimulation, while the focus presently is on ultrasonic assessment of bone for osteoporosis management and ultrasound simulation software. Other areas of development include, among others, inverse scattering and three-dimensional display system technologies. A list of publications and U.S. Patents to which one or more of CyberLogic’s associates has been involved with, or Small Business Innovative Research (SBIR) Grants previously awarded to CyberLogic, may be found in our Bibliography.


CyberLogic is a leader in biomedical and electrical engineering, specializing in state-of-the-art ultrasound technologies for bone health assessment and medical imaging.
UltraScan™ 650 relies on CyberLogic’s patented NTD technology. The NTD is based on measuring transit times of ultrasound signals propagating through the forearm, which allows direct measurement of the amount of bone. The NTD has been validated with computer simulations, in vitro studies, and clinical data, and represents a completely distinct approach to processing of ultrasound data. Conventional bone sonometers evaluate the speed of sound (SOS) and broadband ultrasound attenuation (BUA); these parameters are only weakly correlated with bone mineral density (BMD). In contrast, the high degree of correlation (r = 0.93) of the UltraScan 650 output with BMD is due to the use of the NTD technology. A number of papers and patents related to the NTD technology can be found in the References. Specifically, a summary of the key clinical data can be found in: (A comprehensive paper summarizing the performance of the UltraScan 650 in a clinical trial can be found in our publication by Stein et al. in Ultrasound in Medicine & Biology.) The simulation and in vitro data can be found, respectfully, at: “Ultrasound Simulation in Bone” and “Ultrasonic Assessment of the Radius in vitro”.
